OPKO Health, Inc. (NASDAQ:OPK) CEO Purchases $220,500.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 150,000 shares of the stock in a transaction on Friday, January 17th. The stock was purchased at an average cost of $1.47 per share, for a total transaction of $220,500.00. Following the acquisition, the chief executive officer now owns 213,186,477 shares of the company’s stock, valued at $313,384,121.19. This trade represents a 0.07 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.48 per share, for a total transaction of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock. The shares were bought at an average price of $1.59 per share, for a total transaction of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.56 per share, for a total transaction of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost purchased 199,072 shares of OPKO Health stock. The shares were purchased at an average cost of $1.53 per share, for a total transaction of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The stock was acquired at an average cost of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Stock Performance

Shares of OPK opened at $1.47 on Monday. The stock has a market capitalization of $1.00 billion, a PE ratio of -7.74 and a beta of 1.63. The company’s fifty day moving average is $1.54 and its 200 day moving average is $1.51. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $1.76.

Institutional Trading of OPKO Health

Large investors have recently made changes to their positions in the business. Rubric Capital Management LP grew its position in OPKO Health by 800.0% in the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock worth $55,528,000 after acquiring an additional 39,486,490 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in OPKO Health by 142.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after buying an additional 876,272 shares during the period. Clearline Capital LP bought a new position in OPKO Health during the third quarter valued at $1,083,000. Squarepoint Ops LLC purchased a new stake in shares of OPKO Health in the second quarter valued at $592,000. Finally, Barclays PLC lifted its holdings in shares of OPKO Health by 154.5% in the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after acquiring an additional 329,870 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on OPK. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, January 8th. StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th. Finally, Barrington Research reissued an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.